ID
49
Beschrijving
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation. Inclusion criteria: - Documented (12-lead ECG) history of symptomatic atrial fibrillation occurring between 48 hours and 6 months before screening - Require the procedure of cardioversion (electric shock to correct abnormal rhythm) - In the investigator's opinion, is likely to maintain sinus rhythm after cardioversion. - Be anticoagulated according to the recommendations of the Study Group on Atrial Fibrillation of the European Society of Cardiology guidelines. Exclusion criteria: - Previously unsuccessful electrical cardioversions - Failed to respond to any Class III antiarrhythmic drugs - Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
Trefwoorden
Versies (2)
- 11-11-11 11-11-11 -
- 21-03-14 21-03-14 - Martin Dugas
Geüploaded op
11 november 2011
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0 Legacy
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Criteria NCT00035451 AF
Similar models
Eligibility
- StudyEvent: Eligibility
439401001 (SNOMED CT 2010_0731)
49436004 (SNOMED CT 2010_0731)
10003658 (MedDRA 13.1)
427.31 (ICD-9-CM Version 2011)
I48.0 (ICD-10-CM Version 2010)
E10081 (CTCAE Version 4.03)
46825001 (SNOMED CT 2010_0731)
10014084 (MedDRA 13.1)
250980009 (SNOMED CT 2010_0731)
10007661 (MedDRA 13.1)
LP97905-1 (LOINC Version 232)
260678004 (SNOMED CT 2010_0731)
67507000 (SNOMED CT 2010_0731)
44808001 (SNOMED CT 2010_0731)
10003119 (MedDRA 13.1)
I49.9 (ICD-10-CM Version 2010)
427.9 (ICD-9-CM Version 2011)